Canada Cancer Treatment Market – Industry Trends and Forecast to 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Canada Cancer Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Country Level
  • 350 Páginas
  • Número de tablas: 97
  • Número de figuras: 30

Canada Cancer Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2022 –2029
Diagram Tamaño del mercado (año base)
USD 4,906.97 Million
Diagram Tamaño del mercado (año de pronóstico)
USD 11,108.53 Million
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado de tratamiento del cáncer de Canadá, por tipo de cáncer ( cáncer de mama , cáncer colorrectal con metástasis hepáticas, carcinoma de pulmón cáncer de próstata, cáncer de ovario, cáncer de cabeza y cuello, cáncer de páncreas , glioblastoma, carcinoma de células renales, carcinoma anaplásico de tiroides, sarcoma y otros), tratamiento (medicamentos, terapias dirigidas , radioterapia, cirugía y otros), vía de administración (inyectable, oral y otras), usuario final (hospitales, clínicas especializadas), país (Canadá): tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado: mercado de tratamiento del cáncer en Canadá

Se espera que el mercado de tratamiento del cáncer de Canadá gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 11,1% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 11.108,53 millones para 2029 desde USD 4.906,97 millones en 2021. Es probable que la alta prevalencia del cáncer y el aumento de las actividades de I+D para su aplicación efectiva sean los principales impulsores que impulsen la demanda del mercado en el período de pronóstico.

El cáncer es una enfermedad en la que algunas células del cuerpo crecen sin control y finalmente se propagan a otras partes del cuerpo. El tumor canceroso se propaga a los tejidos cercanos y puede viajar a lugares distantes dentro del cuerpo para formar un nuevo tumor. Este proceso se llama metástasis. El tumor canceroso también se conoce como tumor maligno. El tumor benigno no invade los tejidos cercanos y, cuando se extirpa, los tumores benignos generalmente no vuelven a crecer, mientras que los tumores cancerosos a veces sí lo hacen.

Existen más de cien tipos de cáncer. Algunas categorías de cánceres que comienzan en tipos específicos de células incluyen carcinoma, sarcoma, leucemia, linfoma y mieloma múltiple, entre otros. Existen muchos tipos de cáncer según el tipo de tratamiento contra el cáncer. El tratamiento del cáncer incluye pruebas de biomarcadores, quimioterapia, terapia hormonal, hipertermia, inmunoterapia, terapia fotodinámica, radioterapia, cirugía, trasplante de células madre y terapias dirigidas.

Según GLOBOCAN, en 2020 se detectaron 19.292.789 nuevos casos de cáncer en todo el mundo. Se detectaron los casos más altos de cáncer de mama. Por lo tanto, se espera que la alta prevalencia del cáncer, las iniciativas adoptadas por el gobierno para la concienciación y la detección temprana del cáncer y los ensayos clínicos en curso impulsen el crecimiento del mercado. Se espera que la alta prevalencia del cáncer y el aumento de las iniciativas de concienciación adoptadas por varias organizaciones canadienses actúen como un motor para el crecimiento del mercado. Sin embargo, el alto costo del tratamiento del cáncer puede frenar el crecimiento del mercado. Se espera que el aumento en el lanzamiento de medicamentos contra el cáncer en la región actúe como una oportunidad para el crecimiento del mercado. Sin embargo, los efectos secundarios de los medicamentos pueden desafiar el crecimiento del mercado.

El informe sobre el mercado de tratamiento del cáncer de Canadá proporciona detalles sobre la participación de mercado, los nuevos desarrollos y el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de segmentos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un resumen analítico. Nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado canadiense de tratamiento del cáncerAlcance y tamaño del mercado de tratamiento del cáncer en Canadá

El mercado canadiense de tratamiento del cáncer se clasifica en cuatro segmentos importantes según el tipo de cáncer, el tratamiento, la vía de administración y el usuario final. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

  • Según el tipo de cáncer, el mercado de tratamiento del cáncer de Canadá se segmenta en cáncer de mama, cáncer colorrectal con metástasis hepáticas, carcinoma de pulmón, cáncer de próstata, cáncer de ovario, cáncer de cabeza y cuello, cáncer de páncreas, glioblastoma, carcinoma de células renales, carcinoma anaplásico de tiroides y sarcoma. En 2022, se espera que el segmento del cáncer de mama domine el mercado debido al creciente número de casos de cáncer de mama en Canadá.
  • En función del tratamiento, el mercado canadiense de tratamiento del cáncer se segmenta en medicamentos, terapias dirigidas, radioterapia, cirugía y otros. En 2022, se espera que el segmento de medicamentos domine el mercado debido al lanzamiento de varios medicamentos contra el cáncer en la región.
  • Según la vía de administración, el mercado canadiense de tratamiento del cáncer se segmenta en inyectables, orales y otros. En 2022, se espera que el segmento inyectable domine el mercado, ya que es el fármaco más adecuado para administrar.
  • En función del usuario final, el mercado canadiense de tratamiento del cáncer está segmentado en hospitales y clínicas especializadas. En 2022, se espera que el segmento de hospitales domine el mercado debido a que los hospitales grandes y ricos ofrecen tratamientos avanzados contra el cáncer.

Análisis a nivel de país del mercado de tratamiento del cáncer de Canadá

Se analiza el mercado de tratamiento del cáncer de Canadá y se proporciona información sobre el tamaño del mercado por país, tipo de cáncer, tratamiento, vía de administración y usuario final.

Se espera que Canadá crezca debido al lanzamiento de productos avanzados de tratamiento del cáncer para pacientes.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Canadian brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the Canada Cancer Treatment Market

The Canada cancer treatment market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the dental instruments market. The data is available for the historical period 2011 to 2020.

Competitive Landscape and Canada Cancer Treatment Market Share Analysis

The Canada cancer treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the Canada cancer treatment market.

Some of the major companies in the Canada cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for cancer treatment are bridging the gap for various treatments.

For instance,

  • In December 2020, F. Hoffman-La Roche Ltd. announced that it had received U.S. Food and Drug Administration approval for its drug Gavreto for the treatment of pediatric above the age of 12 years and adult patients with advanced or metastatic rearranged during transfection-mutant medullary thyroid cancer that requires systemic therapy. This has helped the company to increase its portfolio

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the cancer treatment market, which also benefits the organization to improve their offering for the Canada cancer treatment market.

 


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF CANADA CANCER TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 EPIDEMOLOGY

6 CANADA CANCER TREATMENT MARKET: REGULATORY SCENARIO

6.1 TIMELINE TO APPROVE A DRUG

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING CANCER BURDEN WORLDWIDE

7.1.2 GROWING GERIATRIC POPULATION

7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES

7.1.4 RISING NUMBER OF FDA APPROVAL

7.1.5 GROWING R&D ACTIVITIES

7.2 RESTRAINTS

7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS

7.2.2 HIGH COST OF CANCER TREATMENT

7.2.3 LACK OF EARLY DETECTION

7.3 OPPORTUNITIES

7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS

7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS

7.3.3 RISING EXPENDITURE ON CANCER TREATMENT

7.4 CHALLENGES

7.4.1 PATENT EXPIRY OF DRUGS

8 CANADA CANCER TREATMENT MARKET, BY CANCER TYPE

8.1 OVERVIEW

8.2 BREAST CANCER

8.3 COLORECTAL CANCER WITH LIVER METASTASES

8.4 LUNG CARCINOMA

8.5 PROSTATE CANCER

8.6 OVARIAN CANCER

8.7 HEAD-AND-NECK CANCER

8.8 PANCREATIC CANCER

8.9 GLIOBLASTOMA

8.1 RENAL CELL CARCINOMA

8.11 ANAPLASTIC THYROID CARCINOMA

8.12 SARCOMA

9 CANADA CANCER TREATMENT MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.2.1 BY DRUG TYPE

9.2.1.1 lung carcinoma

9.2.1.1.1 Nivolumab (Opdivo)

9.2.1.1.2 Bevacizumab (Avastin)

9.2.1.1.3 Crizotinib (Xalkori)

9.2.1.1.4 Erlotinib (Tarceva)

9.2.1.1.5 Gefitinib (Iressa)

9.2.1.1.6 Afatinib Dimaleate (Gilotrif)

9.2.1.1.7 Ceritinib (Ldk378/Zykadia)

9.2.1.1.8 Ramucirumab (Cyramza)

9.2.1.1.9 others

9.2.1.2 Colorectal Cancer with Liver Metastases

9.2.1.2.1 Nivolumab (Opdivo)

9.2.1.2.2 Cetuximab (Erbitux)

9.2.1.2.3 Panitumumab (Vectibix)

9.2.1.2.4 Bevacizumab (Avastin)

9.2.1.2.5 Ziv-Aflibercept (Zaltrap)

9.2.1.2.6 Regorafenib (Stivarga)

9.2.1.2.7 Ramucirumab (Cyramza)

9.2.1.2.8 Ipilimumab (Yervoy)

9.2.1.2.9 Encorafenib (Braftovi)

9.2.1.2.10 Pembrolizumab (Keytruda)

9.2.1.2.11 others

9.2.1.3 ovarian cancer

9.2.1.3.1 Bevacizumab (Avastin)

9.2.1.3.2 Olaparib (Lynparza)

9.2.1.3.3 Rucaparib Camsylate (Rubraca)

9.2.1.3.4 Niraparib Tosylate Monohydrate (Zejula)

9.2.1.3.5 others

9.2.1.4 head-and-neck cancer

9.2.1.4.1 Cetuximab (Erbitux)

9.2.1.4.2 Pembrolizumab (Keytruda)

9.2.1.4.3 Nivolumab (Opdivo)

9.2.1.4.4 others

9.2.1.5 renal cell carcinoma

9.2.1.5.1 Nivolumab (Opdivo)

9.2.1.5.2 Bevacizumab (Avastin)

9.2.1.5.3 Sorafenib (Nexavar)

9.2.1.5.4 Sunitinib (Sutent)

9.2.1.5.5 Pazopanib (Votrient)

9.2.1.5.6 Temsirolimus (Torisel)

9.2.1.5.7 Everolimus (Afinitor)

9.2.1.5.8 Axitinib (Inlyta)

9.2.1.5.9 Cabozantinib (Cabometyx)

9.2.1.5.10 others

9.2.1.6 anaplastic thyroid carcinoma

9.2.1.6.1 Cabozantinib (Cometriq)

9.2.1.6.2 Vandetanib (Caprelsa)

9.2.1.6.3 Sorafenib (Nexavar)

9.2.1.6.4 Lenvatinib Mesylate (Lenvima)

9.2.1.6.5 Trametinib (Mekinist)

9.2.1.6.6 Dabrafenib (Tafinlar)

9.2.1.6.7 Selpercatinib (Retevmo)

9.2.1.6.8 Pralsetinib (Gavreto)

9.2.1.6.9 others

9.2.1.7 breast cancer

9.2.1.7.1 Everolimus (Afinitor)

9.2.1.7.2 Tamoxifen (Nolvadex)

9.2.1.7.3 Trastuzumab (Herceptin)

9.2.1.7.4 Fulvestrant (Faslodex)

9.2.1.7.5 Anastrozole (Arimidex)

9.2.1.7.6 Exemestane (Aromasin)

9.2.1.7.7 Letrozole (Femara)

9.2.1.7.8 Pertuzumab (Perjeta)

9.2.1.7.9 Palbociclib (Ibrance)

9.2.1.7.10 Ribociclib (Kisqali)

9.2.1.7.11 Tosylate (Talzenna)

9.2.1.7.12 Pembrolizumab (Keytruda)

9.2.1.7.13 Margetuximab-Cmkb (Margenza)

9.2.1.7.14 others

9.2.1.8 prostate cancer

9.2.1.8.1 Cabazitaxel (Jevtana)

9.2.1.8.2 Enzalutamide (Xtandi)

9.2.1.8.3 Abiraterone Acetate (Zytiga)

9.2.1.8.4 Radium 223 Dichloride (Xofigo)

9.2.1.8.5 Apalutamide (Erleada)

9.2.1.8.6 Darolutamide (Nubeqa)

9.2.1.8.7 Rucaparib Camsylate (Rubraca)

9.2.1.8.8 Olaparib (Lynparza)

9.2.1.8.9 others

9.2.1.9 pancreatic cancer

9.2.1.9.1 Erlotinib (Tarceva)

9.2.1.9.2 Everolimus (Afinitor)

9.2.1.9.3 Sunitinib (Sutent)

9.2.1.9.4 Olaparib (Lynparza)

9.2.1.9.5 Belzutifan (Welireg)

9.2.1.9.6 others

9.2.1.10 glioblastoma

9.2.1.10.1 Bevacizumab (Avastin)

9.2.1.10.2 Everolimus (Afinitor)

9.2.1.10.3 Belzutifan (Welireg)

9.2.1.10.4 others

9.2.1.11 sarcoma

9.2.1.11.1 Cosmegen (Dactinomycin)

9.2.1.11.2 Dactinomycin

9.2.1.11.3 Doxorubicin Hydrochloride

9.2.1.11.4 Eribulin Mesylate

9.2.1.11.5 Gleevec (Imatinib Mesylate)

9.2.1.11.6 Halaven (Eribulin Mesylate)

9.2.1.11.7 Imatinib Mesylate

9.2.1.11.8 Pazopanib Hydrochloride

9.2.1.11.9 Tazemetostat Hydrobromide

9.2.1.11.10 Tazverik (Tazemetostat Hydrobromide)

9.2.1.11.11 Trabectedin

9.2.1.11.12 Votrient (Pazopanib Hydrochloride)

9.2.1.11.13 Yondelis (Trabectedin)

9.2.1.11.14 others

9.2.2 BY VACCINES

9.2.2.1 Cervarix

9.2.2.2 Gardasil

9.2.2.3 Gardasil-9

9.2.2.4 Hepatitis B (Hbv) Vaccine (Heplisav-B)

9.2.2.5 Sipuleucel-T (Provenge)

9.2.2.6 others

9.3 RADIOTHERAPY

9.3.1 EXTERNAL BEAM RADIATION THERAPY

9.3.1.1 Three -Dimensional Confromal Radiation Therapy (3-D CRT)

9.3.1.2 Proton Therapy

9.3.1.3 Intensity-Modulated Radiation Therapy (IMRT)

9.3.1.4 Image-Guided Radiation Therapy (IGRT)

9.3.1.5 Tomotherapy

9.3.1.6 Stereotactic Radiosurgery

9.3.1.7 Stereotactic Body Radiation Therapy (SRT)

9.3.1.8 Intraoperative Radiation Therapy

9.3.1.9 others

9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)

9.3.2.1 low-dose-rate (LDR) brachytherapy

9.3.2.2 high-dose-rate (HDR) brachytherapy

9.3.3 SYSTEMIC RADIATION THERAPY

9.3.3.1 peptide receptor radionuclide therapy (PRRT)

9.3.3.2 others

9.4 SURGERY

9.4.1 PAROTIDECTOMY

9.4.2 ENDOSCOPIC SURGERY

9.4.3 NECK DISSECTION

9.4.4 RECONSTRUCTIVE SURGERY

9.4.5 OTHERS

9.5 TARGETED THERAPIES

9.5.1 SMALL MOLECULES

9.5.1.1 tyrosine & serine/threonine kinases

9.5.1.1.1 imatinib (gleevec)

9.5.1.1.2 gefitinib (iressa)

9.5.1.1.3 erlotinib (tarceva)

9.5.1.1.4 sunitinib (sutent)

9.5.1.1.5 perifosine

9.5.1.1.6 others

9.5.1.2 proteosomes

9.5.1.2.1 bortezomib (velcade)

9.5.1.2.2 carfilzomib (kyprolis)

9.5.1.2.3 marizomib

9.5.1.3 MMPS and HSPS

9.5.1.3.1 batimastat

9.5.1.3.2 neovastat

9.5.1.3.3 prinomastat

9.5.1.3.4 rebimastat

9.5.1.3.5 ganetespib

9.5.1.3.6 others

9.5.1.4 apoptosis

9.5.1.4.1 obatoclax

9.5.1.4.2 navitoclax

9.5.1.4.3 others

9.5.2 IMMUNOTHERAPY

9.5.2.1 immune checkpoint inhibitors

9.5.2.2 T-cell transfer therapy

9.5.2.2.1 TIL therapy

9.5.2.2.2 car T-cell therapy

9.5.2.2.3 by product

9.5.2.2.3.1 tisagenlecleucel (kymriah)

9.5.2.2.3.2 axicabtagene ciloleucel (yescarta)

9.5.2.2.3.3 brexucabtagene autoleucel (tecartus)

9.5.2.2.3.4 others

9.5.2.2.4 by technology

9.5.2.2.4.1 autologous

9.5.2.2.4.2 allogeneic

9.5.2.3 monoclonal antibodies

9.5.2.3.1 rituximab

9.5.2.3.2 blinatumomab (blincyto)

9.5.2.3.3 others

9.5.2.4 immune system modulators

9.5.2.4.1 cytokines

9.5.2.4.2 interferons (INFS)

9.5.2.4.3 interleukins (ILS)

9.5.2.4.4 hematopoietic growth factors

9.5.2.4.5 BCG

9.5.2.4.6 immunomodulatory drugs/biological response modifiers

9.5.2.4.7 thalidomide (thalomid)

9.5.2.4.8 lenalidomide (revlimid)

9.5.2.4.9 pomalidomide (pomalyst)

9.5.2.4.10 imiquimod (aldara, zyclara)

9.5.2.4.11 OTHERS

9.5.2.5 treatment vaccines

9.5.2.6 others

9.5.3 HORMONAL THERAPY

9.5.3.1 signal transduction inhibitors

9.5.3.2 gene expression modulators

9.5.3.3 apoptosis inducers

9.5.3.4 angiogenesis inhibitors

9.5.3.5 gene therapy

9.5.3.6 others

9.6 OTHERS

10 CANADA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.3 ORAL

10.4 OTHERS

11 CANADA CANCER TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

12 CANADA CANCER TREATMENT MARKET, BY REGION

12.1 CANADA

13 CANADA CANCER TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: CANADA

14 QUESTIONNAIRE

15 RELATED REPORTS

Lista de Tablas

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 CANADA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 CANADA BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 CANADA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 CANADA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 CANADA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 CANADA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 CANADA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 CANADA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 CANADA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 CANADA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 CANADA SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 CANADA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 CANADA MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 CANADA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 CANADA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 CANADA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 CANADA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 CANADA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 CANADA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 CANADA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 CANADA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 CANADA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 CANADA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 CANADA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 CANADA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 CANADA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 CANADA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 CANADA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 CANADA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 CANADA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 CANADA SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 CANADA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 40 CANADA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 CANADA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 CANADA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 CANADA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 CANADA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 CANADA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 CANADA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 CANADA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 CANADA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 CANADA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 CANADA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 CANADA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 CANADA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 CANADA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 CANADA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 55 CANADA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 CANADA INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 57 CANADA ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 58 CANADA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 59 CANADA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 CANADA HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 61 CANADA SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 62 CANADA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 63 CANADA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 64 CANADA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 CANADA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 CANADA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 CANADA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 CANADA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 CANADA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 CANADA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 CANADA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 CANADA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 CANADA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 CANADA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 CANADA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 CANADA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 CANADA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 CANADA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 CANADA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 CANADA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 CANADA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 CANADA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 CANADA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 CANADA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 CANADA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 CANADA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 CANADA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 CANADA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 90 CANADA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 91 CANADA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 92 CANADA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 93 CANADA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 94 CANADA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 CANADA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 CANADA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 97 CANADA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

Lista de figuras

FIGURE 1 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 2 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: CANADA VS REGIONAL MARKET ANALYSIS

FIGURE 5 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 9 HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 10 BREAST CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN 2022 TO 2029

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF CANADA, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

FIGURE 12 ESTIMATED NUMBER OF NEW CASES AND DEATHS BY VARIOUS TYPES OF CANCER WORLDWIDE, 2020

FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES

FIGURE 14 CANADA CANCER TREATMENT MARKET: BY CANCER TYPE, 2021

FIGURE 15 CANADA CANCER TREATMENT MARKET: BY CANCER TYPE, 2020-2029 (USD MILLION)

FIGURE 16 CANADA CANCER TREATMENT MARKET: BY CANCER TYPE, CAGR (2022-2029)

FIGURE 17 CANADA CANCER TREATMENT MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 18 CANADA CANCER TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 19 CANADA CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 20 CANADA CANCER TREATMENT MARKET: BY TREATMENT CAGR (2022-2029)

FIGURE 21 CANADA CANCER TREATMENT MARKET: BY TREATMENT LIFELINE CURVE

FIGURE 22 CANADA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 CANADA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 24 CANADA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 CANADA CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION LIFELINE CURVE

FIGURE 26 CANADA CANCER TREATMENT MARKET: BY END USER, 2021

FIGURE 27 CANADA CANCER TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 28 CANADA CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 CANADA CANCER TREATMENT MARKET: BY END USER LIFELINE CURVE

FIGURE 30 CANADA CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The market is segmented based on , By Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics), Country (Canada) - Industry Trends and Forecast  to 2029 .
The Canada Cancer Treatment Market size was valued at USD 4906.97 USD Million in 2021.
The Canada Cancer Treatment Market is projected to grow at a CAGR of 11.1% during the forecast period of 2022 to 2029.